NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER

Y. Maruyama; J. R.Van Nagell; E. Donaldson; J. L. Beach; A. Martin; R. Kryscio; J. Yoneda; M. Hanson; J. M. Feola; C. Parker

doi:10.1016/S0140-6736(85)92430-4

NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER

Y. Maruyama, J. R.Van Nagell, E. Donaldson, J. L. Beach, A. Martin, R. Kryscio, J. Yoneda, M. Hanson, J. M. Feola, C. Parker

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Californium-252 (²⁵²Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), ²⁵²Cfintracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.

Original language	English
Pages (from-to)	1120-1122
Number of pages	3
Journal	The Lancet
Volume	325
Issue number	8438
DOIs	https://doi.org/10.1016/S0140-6736(85)92430-4
State	Published - May 18 1985

Bibliographical note

Funding Information:
We thank the US Department of Energy for the 252 caused in this study and the American Cancer Society for financial support of the ongoing randomised clinical trial. We thank Mrs Angela Sandifer for expert assistance. Correspondence should be addressed to Y. M., Department of Radiation Medicine, Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084, USA.

ASJC Scopus subject areas

Medicine (all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(85)92430-4

Cite this

@article{e0b658560f454d918808c7e2d0994926,

title = "NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER",

abstract = "Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cfintracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.",

author = "Y. Maruyama and Nagell, {J. R.Van} and E. Donaldson and Beach, {J. L.} and A. Martin and R. Kryscio and J. Yoneda and M. Hanson and Feola, {J. M.} and C. Parker",

note = "Funding Information: We thank the US Department of Energy for the 252 caused in this study and the American Cancer Society for financial support of the ongoing randomised clinical trial. We thank Mrs Angela Sandifer for expert assistance. Correspondence should be addressed to Y. M., Department of Radiation Medicine, Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084, USA.",

year = "1985",

month = may,

day = "18",

doi = "10.1016/S0140-6736(85)92430-4",

language = "English",

volume = "325",

pages = "1120--1122",

number = "8438",

}

TY - JOUR

T1 - NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER

AU - Maruyama, Y.

AU - Nagell, J. R.Van

AU - Donaldson, E.

AU - Beach, J. L.

AU - Martin, A.

AU - Kryscio, R.

AU - Yoneda, J.

AU - Hanson, M.

AU - Feola, J. M.

AU - Parker, C.

N1 - Funding Information: We thank the US Department of Energy for the 252 caused in this study and the American Cancer Society for financial support of the ongoing randomised clinical trial. We thank Mrs Angela Sandifer for expert assistance. Correspondence should be addressed to Y. M., Department of Radiation Medicine, Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084, USA.

PY - 1985/5/18

Y1 - 1985/5/18

N2 - Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cfintracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.

AB - Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cfintracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021857978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021857978&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(85)92430-4

DO - 10.1016/S0140-6736(85)92430-4

M3 - Article

C2 - 2860334

AN - SCOPUS:0021857978

SN - 0140-6736

VL - 325

SP - 1120

EP - 1122

JO - The Lancet

JF - The Lancet

IS - 8438

ER -

NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this